4.5 Article

Noninvasive Brain Stimulation for Persistent Postconcussion Symptoms in Mild Traumatic Brain Injury

期刊

JOURNAL OF NEUROTRAUMA
卷 32, 期 1, 页码 38-44

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/neu.2014.3449

关键词

rTMS; brain trauma; head injury; concussion; fMRI

资金

  1. Canadian Institutes of Health Research (CIHR)
  2. AstraZeneca
  3. Lundbeck
  4. Sunovion
  5. Eli Lilly
  6. Janssen-Ortho
  7. GlaxoSmithKline
  8. Bristol-Myers Squibb
  9. CIHR

向作者/读者索取更多资源

Mild traumatic brain injury (mTBI) is typically followed by various postconcussive symptoms (PCS), including headache, depression, and cognitive deficits. In 15-25% of cases, PCS persists beyond the usual 3-month recovery period, interfering with activities of daily living and responding poorly to pharmacotherapy. We tested the safety, tolerability, and efficacy of repetitive transcranial magnetic stimulation (rTMS) over the left dorsolateral prefrontal cortex (DLPFC) for alleviating PCS. Fifteen eligible patients with mTBI and PCS>3 months postinjury consented to 20 sessions of rTMS (20x5-sec trains; 10 Hz at 110% threshold), with clinical and functional magnetic resonance imaging (fMRI) assessments before and after intervention and clinical assessment at 3-month follow-up. Primary outcomes were tolerability, safety, and efficacy, as measured with the PCS Scale. Secondary outcomes included the Cognitive Symptoms Questionnaire, neuropsychological test performance, and working memory task-associated activity as assessed with fMRI. Twelve patients completed all sessions. Three withdrew because of worsening symptoms or for an unrelated event. Stimulation intensity was increased gradually across sessions, and all subjects tolerated the protocol by the sixth session. Commonly reported side effects among completers were increased headache (n=3) and greater sleep disturbance (n=3). Participants also reported positive outcomes such as less sleep disturbance (n=3), and better mental focus (n=3). On average, PCS scores declined by 14.6 points (p=0.009) and fMRI task-related activation peaks in the DLPFC increased after rTMS. rTMS is safe, tolerated by most patients with mTBI, and associated with both a reduction in severity of PCS and an increase in task-related activations in DLPFC. Assessment of this intervention in a randomized, control trial is warranted.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据